MAGIC Trial Findings and Perioperative Chemotherapy Regimen
The MAGIC trial established that perioperative chemotherapy with ECF (epirubicin 50 mg/m² IV day 1, cisplatin 60 mg/m² IV day 1, and continuous infusion 5-fluorouracil 200 mg/m²/day for 21 days, repeated every 21 days) significantly improves survival in resectable gastric and gastro-oesophageal junction adenocarcinoma, with 5-year overall survival of 36% versus 23% with surgery alone. 1, 2, 1
Trial Design and Patient Population
The MAGIC trial randomized 503 patients with resectable adenocarcinoma to either:
- Perioperative ECF chemotherapy plus surgery (250 patients)
- Surgery alone (253 patients)
Patient distribution included 1, 3:
- 74% gastric cancer
- 14% lower esophageal cancer
- 11% gastro-oesophageal junction cancer
- Stage II or higher (M0) disease or locally advanced inoperable disease
ECF Chemotherapy Regimen Specifics
The perioperative protocol consisted of 1, 2, 4, 3:
Three preoperative cycles:
- Epirubicin 50 mg/m² IV on day 1
- Cisplatin 60 mg/m² IV on day 1
- 5-Fluorouracil 200 mg/m²/day continuous IV infusion for 21 days
- Repeated every 21 days
Surgery
Three postoperative cycles (same regimen)
Treatment Completion Rates
- Only 41.6% of patients completed all six cycles of chemotherapy 2
- 49.5% of patients who completed preoperative ECF also completed postoperative therapy 2
- 68% underwent curative surgery 2
Key Survival Outcomes
The trial demonstrated significant improvements in mortality and disease progression 1, 2, 1, 3:
Overall Survival:
- 5-year survival: 36% (perioperative ECF) vs 23% (surgery alone)
- Hazard ratio for death: 0.75 (95% CI 0.60-0.93; P=0.009)
- Median survival: 36 months vs 27 months
Progression-Free Survival:
- Hazard ratio: 0.66 (95% CI 0.53-0.81; P<0.001)
Pathological Response:
- Greater proportion of T1 and T2 tumors in chemotherapy group (51.7% vs 36.8%) 2, 5
- Less advanced nodal disease (N0 or N1: 84% vs 70.5%) 5
Toxicity Profile
Grade 3-4 adverse events in the perioperative chemotherapy arm included 2:
- Granulocytopenia: 22.8-27.8%
- Lymphocytopenia: 16.9-19.9%
- Leukopenia: 11.1-11.5%
- Nausea: 6.4-12.3%
- Vomiting: 5.6-10.1%
Critical finding: Postoperative complication rates were similar between groups (46% perioperative chemotherapy vs 45% surgery alone), with comparable 30-day mortality 3.
Clinical Practice Implications
Perioperative chemotherapy with ECF became an established standard of care throughout Europe for resectable gastric and gastro-oesophageal junction adenocarcinoma 1, 4. Many centers subsequently adopted ECX (substituting capecitabine for 5-FU) to avoid central venous access requirements 4.
Important Caveats
The trial had notable limitations 2:
- Low completion rate of full perioperative treatment (41.6%)
- Only 68% underwent curative surgery
- No heterogeneity of treatment effect by disease site (interaction p=0.25), though subgroup analyses were limited
- Results established perioperative chemotherapy as "another added option" rather than the sole standard 1
Modern Context
While MAGIC established perioperative chemotherapy as standard, more recent evidence shows FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) achieves superior outcomes compared to ECF 6, 7, 8. The FLOT4 trial demonstrated 5-year survival of 45% with FLOT versus 36% with ECF/ECX, making FLOT the current preferred perioperative regimen when tolerable 6.